Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses
| dc.contributor.author | Awad Ahmed M. | |
| dc.contributor.author | Hansen Kamryn | |
| dc.contributor.author | Del Rio Diana | |
| dc.contributor.author | Flores Derek | |
| dc.contributor.author | Barghash Reham F. | |
| dc.contributor.author | Kakkola Laura | |
| dc.contributor.author | Julkunen Ilkka | |
| dc.contributor.author | Awad Kareem | |
| dc.contributor.organization | fi=InFLAMES Lippulaiva|en=InFLAMES Flagship| | |
| dc.contributor.organization | fi=biolääketieteen laitos|en=Institute of Biomedicine| | |
| dc.contributor.organization | fi=tyks, vsshp|en=tyks, varha| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.68445910604 | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.77952289591 | |
| dc.converis.publication-id | 181911781 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/181911781 | |
| dc.date.accessioned | 2025-08-28T01:44:30Z | |
| dc.date.available | 2025-08-28T01:44:30Z | |
| dc.description.abstract | <p>In light of the COVID-19 global pandemic caused by SARS-CoV-2, ongoing research has centered on minimizing viral spread either by stopping viral entry or inhibiting viral replication. Repurposing antiviral drugs, typically nucleoside analogs, has proven successful at inhibiting virus replication. This review summarizes current information regarding coronavirus classification and characterization and presents the broad clinical consequences of SARS-CoV-2 activation of the angiotensin-converting enzyme 2 (ACE2) receptor expressed in different human cell types. It provides publicly available knowledge on the chemical nature of proposed therapeutics and their target biomolecules to assist in the identification of potentially new drugs for the treatment of SARS-CoV-2 infection. <br></p> | |
| dc.identifier.eissn | 2218-273X | |
| dc.identifier.jour-issn | 2218-273X | |
| dc.identifier.olddbid | 207990 | |
| dc.identifier.oldhandle | 10024/191017 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/57386 | |
| dc.identifier.url | https://www.mdpi.com/2218-273X/13/10/1452 | |
| dc.identifier.urn | URN:NBN:fi-fe2025082791844 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Kakkola, Laura | |
| dc.okm.affiliatedauthor | Julkunen, Ilkka | |
| dc.okm.affiliatedauthor | Awad, Kareem | |
| dc.okm.affiliatedauthor | Dataimport, tyks, vsshp | |
| dc.okm.discipline | 1182 Biochemistry, cell and molecular biology | en_GB |
| dc.okm.discipline | 3111 Biomedicine | en_GB |
| dc.okm.discipline | 317 Pharmacy | en_GB |
| dc.okm.discipline | 1182 Biokemia, solu- ja molekyylibiologia | fi_FI |
| dc.okm.discipline | 3111 Biolääketieteet | fi_FI |
| dc.okm.discipline | 317 Farmasia | fi_FI |
| dc.okm.internationalcopublication | international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A2 Scientific Article | |
| dc.publisher | Frontiers MDPI | |
| dc.publisher.country | Switzerland | en_GB |
| dc.publisher.country | Sveitsi | fi_FI |
| dc.publisher.country-code | CH | |
| dc.publisher.place | Switzerland | |
| dc.relation.articlenumber | 1452 | |
| dc.relation.doi | 10.3390/biom13101452 | |
| dc.relation.ispartofjournal | Biomolecules | |
| dc.relation.issue | 10 | |
| dc.relation.volume | 13 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/191017 | |
| dc.title | Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses | |
| dc.year.issued | 2023 |
Tiedostot
1 - 1 / 1